If you searched "TB-500 research" this week, almost everything you'd find talks about tendons, tears and recovery. The actual human trial programme for thymosin beta-4 is happening somewhere else entirely: on the surface of the eye. Every completed, controlled efficacy trial of this molecule has tested it as a preservative-free eye drop — and that programme has just posted another miss. If you want to understand what is genuinely known about TB-500 in Australia, the eye data is the only human evidence there is, and it is a mixed record rather than a success story.

What is TB-500, and what are the trials actually testing?

Thymosin beta-4 (Tβ4) is a small, naturally occurring 43-amino-acid actin-sequestering protein found in most human cells. The clinical candidate built on it is RGN-259, a 0.1% synthetic thymosin beta-4 ophthalmic solution, developed by RegeneRx and licensed to ReGenTree, a joint venture with Korea's HLB Therapeutics.

That is the molecule in the trials: the full-length protein, applied topically to the ocular surface, several times a day.

"TB-500" as the term is used in the peptide market generally isn't that. It's the name attached to material sold as a shorter synthetic fragment, injected systemically for musculoskeletal claims that no trial in this programme has tested. We've unpacked the naming problem in detail on the TB-500 profile page, but the short version matters here: a positive eye-drop result would not automatically transfer to a different molecule, a different route and a different tissue.

The Phase 3 record: one win, two misses

Dry eye (ARISE-1, -2, -3)

The largest push was in dry eye disease. ARISE-3 enrolled roughly 700 patients and, on topline analysis, did not meet its pre-specified co-primary endpoints. The sponsor reported statistically significant improvement in ocular grittiness — a pre-specified secondary symptom endpoint — at one and two weeks and after controlled adverse-environment exposure, along with a clean safety profile with no serious adverse events. Pooled analyses across all three trials covered approximately 1,500 patients.

Read that honestly: a programme of that size, with a benign safety record, that still could not clear its own primary bar. Post-hoc and secondary endpoints are hypothesis-generating, not proof. No dry eye product containing thymosin beta-4 has been approved anywhere.

Neurotrophic keratitis (SEER-1, SEER-3)

The pivot was to neurotrophic keratopathy, a rare corneal disease where the damage is nerve-driven and healing is measurable. A small randomised, double-masked, placebo-controlled Phase 3 (SEER-1) reported that 0.1% RGN-259 promoted healing of persistent epithelial defects and improved patient comfort versus placebo — a genuinely positive result, but in a very small population, as rare-disease trials tend to be.

The European Phase 3, SEER-3, did not repeat it. Seventy-eight patients across 25 hospitals in Spain, Italy, Poland and Germany; the primary endpoint was complete corneal healing at four weeks; the trial did not show a statistically significant difference versus placebo. A company spokesperson attributed the result to a stronger-than-expected placebo response in the control arm.

That explanation may well be right — high placebo healing rates are a known problem in corneal defect trials. But it is a company's interpretation of topline data, offered after the fact, not a published finding. The sponsor has said it will focus resources on the ongoing US Phase 3, SEER-2, which is where the programme's fate now sits.

Why none of this supports the injury-recovery use

This is the part worth sitting with. The most advanced thymosin beta-4 evidence in the world is:

  • Topical, not injected — drops onto an exposed epithelial surface, with no systemic exposure claim
  • Full-length Tβ4, not the fragment sold under the TB-500 name
  • Corneal wound healing, not tendon, ligament or muscle repair
  • Still unapproved, after three Phase 3 dry eye trials and two in keratitis

There are no completed human efficacy trials supporting the use of TB-500 for soft-tissue injury recovery. The tendon and muscle claims trace to animal and cell work — largely rodent models of wound, cardiac and tissue injury — which is a legitimate place for a hypothesis to start and an illegitimate place for a marketing claim to finish. Preclinical is preclinical. You can browse how that pattern repeats across the wider peptides section.

Is TB-500 legal in Australia? The Appendix D position hasn't moved

Australia's regulatory answer is unusually blunt, and none of the ophthalmology news changes it.

Following consideration by the scheduling delegate in 2016, thymosin beta 4 and TB-500 were captured in Schedule 4 and in Appendix D, Item 5 of the Poisons Standard — the category covering substances for which possession without authority is illegal. The stated rationale referenced growth-factor effects on muscle, tendon, ligament and vascularisation, and illicit use to enhance sporting performance. Appendix D is a materially stronger control than ordinary prescription-only status: it is not simply "you need a script", it is a possession offence absent lawful authority.

The sporting overlay is equally settled. Thymosin beta-4 is prohibited at all times under the WADA List, and in January 2016 the Court of Arbitration for Sport upheld anti-doping violations against 34 Essendon players in a matter centred on this compound — still the defining Australian case on the substance.

There is no thymosin beta-4 product on the ARTG. And it's worth being precise about the upside case: if SEER-2 reads out positive and a product is eventually approved overseas, what exists at the end of that road is a prescription eye drop for a rare corneal disease, requiring its own TGA evaluation for Australian supply. It would not be an injectable recovery peptide, and it would not alter the Appendix D status of the material sold under the TB-500 name.

What to watch next

The SEER-2 readout is the single most informative event coming in this space. A win would give thymosin beta-4 its first credible, replicated human efficacy signal in nearly two decades of development. A second miss would make the SEER-1 result look increasingly like an outlier from a small trial.

Either way, the result speaks to corneal healing. Anyone extrapolating it to a shoulder injury is doing the extrapolating themselves.

For plain-English breakdowns of readouts like this as they land, join the free updates list.

FAQ

What is TB-500?

TB-500 is the market name for synthetic material based on thymosin beta-4, a naturally occurring 43-amino-acid actin-binding protein. The clinical trials use full-length thymosin beta-4 as a topical eye drop (RGN-259), which is not the same product or route as injected TB-500.

Is TB-500 legal in Australia?

No, not for general possession. Thymosin beta 4 and TB-500 sit in Schedule 4 and Appendix D, Item 5 of the Poisons Standard, meaning possession without lawful authority is illegal, and no thymosin beta-4 product is registered on the ARTG.

Does TB-500 heal injuries?

There is no completed human efficacy trial supporting TB-500 for tendon, muscle or ligament injury. The injury-recovery claims rest on animal and cell-culture research, which cannot establish clinical benefit in people.

Is TB-500 banned in sport?

Yes. Thymosin beta-4 is prohibited at all times under the WADA List, and in January 2016 the Court of Arbitration for Sport upheld anti-doping violations against 34 Essendon players in a case centred on the compound.

Sources

This article is information only, not medical advice, and retatrutide.net.au is independent and not affiliated with any manufacturer. Thymosin beta-4 / TB-500 is not an approved therapeutic good in Australia, is controlled under Schedule 4 and Appendix D of the Poisons Standard, and is prohibited in sport.